has called for more investment in training clinical coders.
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We have no conflicting interests to declare. This work has not been presented earlier. Sir, Delayed, rapid visual field loss in a patient after ten years of vigabatrin therapy Vigabatrin is associated with the development of visual field loss (VFL) in 25-50% of patients. 1 VFL is suggested to be stable with continued use of vigabatrin.
2,3
Case report A 36-year-old female receiving 3000 mg/day of vigabatrin since 1992 as add-on therapy for partial epilepsy was referred in 1998 for visual field (VF) monitoring. At the time of referral the patient had no visual complaints, visual acuity was 6/6 in both eyes, colour vision and discs were normal.
Serial assessment between 1998 and 2008 using Goldmann kinetic perimetry showed a rapid deterioration in VFs between assessments a year apart between 2002 and 2003, after 10 years of vigabatrin therapy and earlier stable VFs 
Comment
Onset of VFL after initiating vigabatrin has been reported as early as 6 weeks, 4 but commonly becomes evident within the first few years. 4, 5 Prospective studies of patients with established vigabatrinassociated VFL suggest that the field defect is stable and irreversible and does not progress further with continued treatment. 2, 3 However, observation periods are usually shorter than the one reported here. On the basis of this evidence, guidelines from the Royal College of Ophthalmologists suggest six monthly visual field screening for the first 5 years of treatment and yearly screening thereafter. 6 The case reported here shows that severe VFL can occur after many years of treatment and earlier stable visual function. This may suggest that yearly screening in those patients who continue to take vigabatrin for more than 5 years may not be sufficient to detect rapid changes in VFs. Additional, long-term observational studies are needed to further elucidate the nature of vigabatrinassociated VFL. Figure 2 Retinal nerve fibre layer thickness average analysis report for both eyes taken from a fast retinal nerve fibre layer scan using optical coherence tomography. The analysis shows bilateral and symmetrical thinning of the retinal nerve fibre layer with relative sparing of the temporal quadrant.
